NASDAQ:CLSNCelsion Stock Price, Forecast & News

Celsion's stock was trading at $0.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CLSN shares have increased by 191.9% and is now trading at $2.89. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Celsion.

Celsion is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Celsion.

Celsion Co. (NASDAQ:CLSN) issued its quarterly earnings results on Thursday, March, 26th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.10. The biotechnology company had revenue of $0.13 million for the quarter, compared to analysts' expectations of $0.13 million. Celsion had a negative return on equity of 120.14% and a negative net margin of 3,908.00%. View Celsion's earnings history.

Shares of Celsion reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

Media headlines about CLSN stock have trended positive on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celsion earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutCelsion.

Some companies that are related to Celsion include Selecta Biosciences (SELB), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), Geron (GERN), Avadel Pharmaceuticals (AVDL), TherapeuticsMD (TXMD), Ovid Therapeutics (OVID), MannKind (MNKD), Menlo Therapeutics (MNLO), Concert Pharmaceuticals (CNCE), Lannett (LCI), OrganiGram (OGI), Osmotica Pharmaceuticals (OSMT), Avid Bioservices (CDMO) and Neptune Wellness Solutions (NEPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Amarin (AMRN), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY) and Novavax (NVAX).

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Celsion's stock is owned by many different institutional and retail investors. Top institutional shareholders include Eudaimonia Partners LLC (0.29%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper. View institutional ownership trends for Celsion.

CLSN stock was bought by a variety of institutional investors in the last quarter, including Eudaimonia Partners LLC. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno, and Robert W Hooper. View insider buying and selling activity for Celsion.

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLSN stock can currently be purchased for approximately $2.89.

Celsion has a market capitalization of $84.55 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Celsion employs 29 workers across the globe.

The official website for Celsion is www.celsion.com.

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]